Scandion Oncology A/S/News/BioStock Studio: Scandion Oncology pushes forward with confidence

BioStock Studio: Scandion Oncology pushes forward with confidence

29 June 2020 - 08:21

Scandion Oncology has been very active of late, which has had significant effect on the company share. BioStock was happy to welcome CEO Nils Brünner back to the BioStock studio to give us some background about the company and discuss what makes Scandion Oncology an attractive investment.

Watch the video interview with Scandion Oncology's CEO Nils Brünner at biostock.se:

https://www.biostock.se/en/biostock-studio-scandion-oncology-pushes-forward-with-confidence/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Provided by: Cision

Scandion Oncology A/S

Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen....

Learn more about company

Related news

02.07.2020

Iconovo AB

Stevanato to invest in ICOcap® manufacturing

Stevanato announced in their industrial plan for 2020 – 2023 that they intend to invest almost Euro 400 million in manufacturing and R&D programs for drug delivery systems. A share of this investment will be allocated to the manufacturing of ICOcap®. This update follows the announcement May 27 t...

02.07.2020

Iconovo AB

Stevanato beslutar om investering i ICOcap® tillverkning

Stevanato meddelade i sin industriella plan för 2020 – 2023 att de avser investera nästan Euro 400 miljoner i tillverkning och FoU program för drug delivery system. En del av denna investering avser tillverkning av ICOcap®. Denna uppdatering följer på pressmeddelandet från 27 maj att ICOcap® hade er...

02.07.2020

Stayble Therapeutics AB

Stayble’s clinical phase 2b study has now also started in the Netherlands

The primary goal of the phase 2b trial is to demonstrate safety, tolerability and a clinically relevant reduction in pain in patients. The study will include some 100 patients and will be conducted at about 20 clinical sites in the Netherlands, Russia and Spain. The Company aims to recruit these pat...

02.07.2020

Stayble Therapeutics AB

Staybles kliniska fas 2b-studie har nu också startat i Nederländerna

Målet med den kliniska fas 2b-studien är att påvisa säkerhet, tolerabilitet och kliniskt relevant minskning i smärta efter behandling med STA363 i patienter med kronisk diskrelaterad ryggsmärta. Studien kommer att inkludera c:a 100 patienter och genomföras vid c:a 20 kliniker i Nederländerna, Ryssla...